(grade 2), anemia (grade 1), but no hyperlymphocytosis. The physical examination confirmed the progression of CLL under ibrutinib with an enlarged spleen, palpable axillary, and cervical adenopathies. The neurological examination was also abnormal with decreased left upper limb strength (with pyramidal syndrome), left hemianopsia, and visual hallucinations. Bone marrow aspiration detected 12% lymphocytes (including 25% with CLL phenotype, TP53 exon 5 mutation VAF = 1.5%, considered as a minor bone marrow infiltration). A lumbar puncture found no evidence of CLL or infection. The spleen biopsy confirmed the relapse diagnosis and "accelerated CLL" features but did not support a Richter transformation (PET/CT showed no additional FDG avid lesions). The brain MRI confirmed an increased signal in the right parietotemporal leptomeninx in FLAIR and diffusion sequences. The electroencephalogram (EEG) showed generalized periodic epileptiform discharges, which were more prominent in the right cerebral hemisphere, suggestive of cerebral injury. Additional tests were performed to attribute a differential diagnosis: bacterial, mycobacterial, F I G U R E 1 Brain magnetic resonance imaging (MRI) of central nervous system involvement (CNSi) became apparent during ibrutinib therapy and was treated with high-dose methotrexate, rituximab, and venetoclax. A, Brain MRI scans at diagnosis of the CNSi, showing increased signal intensity in the right parietotemporal leptomeninx and parenchyma on FLAIR and diffusion sequences, with no restriction in ADC sequence, no vascular enhancement in postcontrast T1-weighted sequence, and no perfusion abnormality, favoring a meningoencephalitis diagnosis. These results confirmed the diagnosis of CLL relapse with nodal, splenic, and CNS involvement after two years of ibrutinib treatment. This is the first such case encountered in our hospital among 150 patients treated with ibrutinib. Ibrutinib is indeed reported to show efficacy in the management of mantle cell lymphoma, Waldenström disease, and CLL progression in the CNS. Ibrutinib was discontinued at the beginning of the patient's hospitalization and corticotherapy promptly initiated and then progressively tapered. The patient received two cycles of high-dose IV methotrexate (2 g/m 2 day 1-15) and rituximab (375 mg/m 2 day 1 of the first cycle, then 500 mg/m 2 day 1 of the second cycle). On day 5 of cycle 1 the patient was started on venetoclax, according to the following protocol:
• 20 mg per day: 1 day • 50 mg per day: 5 days • 100 mg per day: 13 days • 200 mg per day: continuously Initially, no significant adverse events occurred more specifically no clinical or biological tumor lysis syndrome was observed. After 3 weeks, a persistent grade 3 neutropenia partially due to drug-drug interactions with antiepileptic agents (lacosamide, levetiracetam, and valpromide) prevented us from achieving the recommended 400 mg/day threshold. The grade 2 thrombocytopenia remained stable.
Three weeks after starting treatment, despite an initial improvement of all symptoms, the patient suddenly relapsed presenting with the previously described neurological deficiencies. EEG was deemed unchanged. The brain MRI showed local modifications of the previously identified parietotemporal leptomeninx lesion suggestive of a necrotizing lesion. There was no radiological argument in favor of CLL progression nor of ischemic stroke. Figure 1 illustrates the evolution of CNS involvement on the brain MRI during the first three months of treatment. It highlights the paradoxical response after three weeks of treatment with sudden worsening of neurological deficiencies and laminar necrosis of the tumor on cerebral MRI scans.
The patient's neurological condition improved and allowed him to be discharged from hospital indefinitely. The patient continues to take venetoclax at the dose of 200 mg/ day. He has received six cycles of rituximab in total and continues to take oral prednisone (0.5 mg/kg per day). Clinically, a left-inferior hemianopsia is still apparent at 6 months and appears to be the only sequelae. The evolution of the patient's response and the timing of treatment is illustrated in Figure 2 .
F I G U R E 2 Timeline graph of the treatment and results
Diagnosis work-up of CLL relapse with CNS involvement during ibruƟnib therapy Our report confirms the potency of venetoclax + rituximab to efficiently cross the blood-brain barrier for the management of CLL with CNS involvement. Nevertheless, the initial contribution of methotrexate infusions and continuous oral corticosteroids cannot be ruled out to explain the clinical improvement. Indeed, previously reported cases show that intrathecal chemotherapy (methotrexate and cytarabine) is the most frequently given treatment for CLL with CNS involvement. 9,10 Our patient's previous medical history of psychiatric disorders complicated the interpretation and feasibility of lumbar punctures. Moreover, splenomegaly and palpable adenopathies suggested a systemic progression which was confirmed by the splenic biopsy. Therefore, we decided on a systemic chemotherapy with a well-established CSF penetration. Although cyclophosphamide and fludarabine are the most frequently used systemic chemotherapies in these cases, as stated in the literature, 4 this approach was precluded in our patient as he had experienced major side effects with these drugs in the past. Consequently, high-dose methotrexate was prescribed as an alternative as it is a well-accepted treatment for managing CNS involvement in other aggressive B-cell malignancies notwithstanding the absence of reports of its use in CLL. The management of systemic relapse after ibrutinib treatment was completed with rituximab and venetoclax as described by Seymour et al. 11 There is evidence supporting the use of rituximab to treat CNS involvement of B-cell malignancies such as primary CNS lymphoma. 12 But, the potency of venetoclax in treating CNS involvement as described by Reda et al 7 was not known at the beginning of our patient's treatment. As a matter of fact, the need to quickly control neurological symptoms was another argument in favor of the administration of high-dose methotrexate in our case. The contribution of intravenous methotrexate along with corticosteroids to control neurologic deficiencies at the diagnosis of CNS involvement is well-established in contrast to venetoclax. However, six months after the last methotrexate infusion and under continuous venetoclax treatment neurologic improvements are stable and there are no sequelae nor have any new symptoms arisen. This suggests that venetoclax is effective for treating CNS involvement of CLL. We also highlight the absence of any major side effects. We expect venetoclax to be beneficial as a long-term control strategy especially in our case in which the patient progressed under ibrutinib treatment.
| CONCLUSION
Venetoclax in combination with rituximab and high-dose methotrexate may be an effective and safe therapeutic option to manage CNS involvement of CLL.
